Literature DB >> 29801663

Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium.

William A Pearce1, Rui Chen2, Nieraj Jain3.   

Abstract

PURPOSE: To describe the clinical features of a unique pigmentary maculopathy noted in the setting of chronic exposure to pentosan polysulfate sodium (PPS), a therapy for interstitial cystitis (IC).
DESIGN: Retrospective case series. PARTICIPANTS: Six adult patients evaluated by a single clinician between May 1, 2015, and October 1, 2017.
METHODS: Patients were identified by query of the electronic medical record system. Local records were reviewed, including results of the clinical examination, retinal imaging, and visual function assessment with static perimetry and electroretinography. Molecular testing assessed for known macular dystrophy and mitochondrial cytopathy genotypes. MAIN OUTCOME MEASURES: Mean best-corrected visual acuity (BCVA; in logarithm of the minimum angle of resolution units), median cumulative PPS exposure, subjective nature of the associated visual disturbance, qualitative examination and imaging features, and molecular testing results.
RESULTS: The median age at presentation was 60 years (range, 37-62 years). All patients received PPS for a diagnosis of IC, with a median cumulative exposure of 2263 g (range, 1314-2774 g), over a median duration of exposure of 186 months (range, 144-240 months). Most patients (4 of 6) reported difficulty reading as the most bothersome symptom. Mean BCVA was 0.1±0.18 logarithm of the minimum angle of resolution. On fundus examination, nearly all eyes showed subtle paracentral hyperpigmentation at the level of the retinal pigment epithelium (RPE) with a surrounding array of vitelliform-like deposits. Four eyes of 2 patients showed paracentral RPE atrophy, and no eyes demonstrated choroidal neovascularization. Multimodal retinal imaging demonstrated abnormality of the RPE generally contained in a well-delineated area in the posterior pole. None of the 4 patients who underwent molecular testing of nuclear DNA returned a pathogenic mutation. Additionally, all 6 patients showed negative results for pathogenic variants in the mitochondrial gene MTTL1.
CONCLUSIONS: We describe a novel and possibly avoidable maculopathy associated with chronic exposure to PPS. Patients reported symptoms of difficulty reading and prolonged dark adaptation despite generally intact visual acuity and subtle funduscopic findings. Multimodal imaging and functional studies are suggestive of a primary RPE injury. Additional investigation is warranted to explore causality further.
Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29801663     DOI: 10.1016/j.ophtha.2018.04.026

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  20 in total

1.  Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis.

Authors:  George Goucher; Fred Saad; Himu Lukka; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2019-02       Impact factor: 1.862

2.  Chronic use of pentosan polysulfate sodium associated with risk of vision-threatening disease.

Authors:  Tanner J Ferguson; Ryan L Geraets; Matthew A Barker
Journal:  Int Urogynecol J       Date:  2019-01-05       Impact factor: 2.894

3.  Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort.

Authors:  Nieraj Jain; Alexa L Li; Yinxi Yu; Brian L VanderBeek
Journal:  Br J Ophthalmol       Date:  2019-11-06       Impact factor: 4.638

4.  Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation.

Authors:  Rachel Shah; Joseph M Simonett; Riley J Lyons; Rajesh C Rao; Mark E Pennesi; Nieraj Jain
Journal:  JAMA Ophthalmol       Date:  2020-08-01       Impact factor: 7.389

5.  Possible drug-induced, vision-threatening maculopathy secondary to chronic pentosan polysulfate sodium (Elmiron®) exposure.

Authors:  R Christopher Doiron; Mark Bona; J Curtis Nickel
Journal:  Can Urol Assoc J       Date:  2020-01-07       Impact factor: 1.862

Review 6.  Age-Related Macular Degeneration Masquerade: A Review of Pentosan Polysulfate Maculopathy and Implications for Clinical Practice.

Authors:  Chirantan Mukhopadhyay; Timothy M Boyce; Karen M Gehrs; James C Folk; Robert F Mullins; Yi Luo; Karl Kreder; Elliott H Sohn
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2022 Mar-Apr 01

Review 7.  Clinical Management of Bladder Pain Syndrome/Interstitial Cystitis: A Review on Current Recommendations and Emerging Treatment Options.

Authors:  Josie Colemeadow; Arun Sahai; Sachin Malde
Journal:  Res Rep Urol       Date:  2020-08-18

8.  Managing Interstitial Cystitis/Bladder Pain Syndrome in Older Adults.

Authors:  Alyssa Gracely; Anne P Cameron
Journal:  Drugs Aging       Date:  2020-10-23       Impact factor: 3.923

9.  Pentosan associated retinal pigmentary changes: FDA's perspective on an emerging postmarketing safety finding.

Authors:  Allison Lardieri; Karen Konkel; Lynda McCulley; S Christopher Jones; David Moeny; Christine Nguyen; Catherine Sewell; Wiley Chambers; Adebola Ajao
Journal:  Int Urogynecol J       Date:  2021-09-10       Impact factor: 2.894

10.  PENTOSAN POLYSULFATE AND VISION: Findings from an International Survey of Exposed Individuals.

Authors:  Ogul E Uner; Megha K Shah; Nieraj Jain
Journal:  Retina       Date:  2021-07-01       Impact factor: 3.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.